Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 1/20 | 0.51 |
| ▸ | TNFRSF1A | P19438 | 3/20 | 0.49 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.46 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.46 |
| ▸ | F3 | P13726 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3969812 | 0.89 | CAPN1 (0.45) | MAOBMAPTMAOANPC1RAB9A | |
| SCHEMBL1778808 | 0.88 | CA1 (0.48) | KRASTNFRSF1AABCG2MAOBALDH1A1 | |
| SCHEMBL3964836 | 0.88 | ALDH1A1 (0.48) | KRASTNFRSF1AABCG2MAOBALDH1A1 | |
| SCHEMBL498833 | 0.88 | MAPT (0.44) | MAOBALDH1A1MAPTCYP1B1MAOA | |
| SCHEMBL3972097 | 0.88 | LMNA (0.46) | KRASABCG2MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL3969980 | 0.88 | CXCL12 (0.41) | KRASABCG2ALDH1A1SMN1; SMN2CXCL12 | |
| SCHEMBL499277 | 0.88 | CA1 (0.48) | KRASTNFRSF1AABCG2MAOBALDH1A1 | |
| SCHEMBL1933383 | 0.88 | CYP1A1 (0.39) | KRASTNFRSF1AGABRA3GABRA2GABRB2 | |
| SCHEMBL29382056 | 0.88 | CYP1A1 (0.39) | KRASTNFRSF1AGABRA3GABRA2GABRB2 | |
| SCHEMBL3968303 | 0.87 | ABCG2 (0.47) | ABCG2MAOBALDH1A1MAPTCYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221751-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | GENFIT (FR) | 2015-12-29 | — | — | US | claimed |
| US-7566737-B2 | Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2009-07-28 | — | — | US | claimed |
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2007-02-08 | — | — | US | claimed |
| US-20200384105-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2020-12-10 | — | — | US | disclosed |
| US-10350181-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | GENFIT (FR) | 2019-07-16 | — | — | US | disclosed |
| US-20180280328-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2018-10-04 | — | — | US | disclosed |
| US-10022343-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | GENFIT (FR) | 2018-07-17 | — | — | US | disclosed |
| US-20170368007-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2017-12-28 | — | — | US | disclosed |
| US-9782373-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | GENFIT (FR) | 2017-10-10 | — | — | US | disclosed |
| US-20170128399-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2017-05-11 | — | — | US | disclosed |
| US-9585853-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | GENFIT (FR) | 2017-03-07 | — | — | US | disclosed |
| US-20160051501-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2016-02-25 | — | — | US | disclosed |
| US-9221751-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | GENFIT (FR) | 2015-12-29 | — | — | US | disclosed |
| US-20150051145-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2015-02-19 | — | — | US | disclosed |
| US-7566737-B2 | Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2009-07-28 | — | — | US | disclosed |
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170368007-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT2, GOT1 | KRAS 4681/4885TNFRSF1A 3393/4885GABRA3 4375/4885 |
| US-20170128399-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT2, GOT1 | KRAS 4681/4885TNFRSF1A 3393/4885GABRA3 4375/4885 |
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | PSEN1, BACE1, PSEN2 | KRAS 2652/4885TNFRSF1A 2548/4885GABRA3 4275/4885 |
| US-20160051501-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT2, GOT1 | KRAS 4681/4885TNFRSF1A 3393/4885GABRA3 4375/4885 |
| US-20150051145-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT2, GOT1 | KRAS 4681/4885TNFRSF1A 3393/4885GABRA3 4375/4885 |
| US-20180280328-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT2, GOT1 | KRAS 4681/4885TNFRSF1A 3393/4885GABRA3 4375/4885 |
| US-20200384105-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT2, GOT1 | KRAS 4681/4885TNFRSF1A 3393/4885GABRA3 4375/4885 |
| US-10350181-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | FABP1, GOT2, GOT1 | KRAS 4681/4885TNFRSF1A 3393/4885GABRA3 4375/4885 |
| US-10022343-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | FABP1, GOT2, GOT1 | KRAS 4681/4885TNFRSF1A 3393/4885GABRA3 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.